Reliability of Dosing With NovoLog® Mix 70/30 FlexPen® Compared With Vial and Syringe

Novo Nordisk

Status and phase: Completed; Phase 1

Conditions: Diabetes; Diabetes Mellitus, Type 2; Delivery Systems

Treatments: Device: vial and syringe; Device: FlexPen®

Study type: Interventional

Funder types: Industry

Identifiers

NCT00127296

BIASP-1654

Details and patient eligibility

About

This trial is conducted in the United States of America (USA). The aim of this trial is to compare desired (target) with actual target amounts of insulin dispensed using NovoLog® Mix 70/30 FlexPen® and vial and syringe in subjects with type 2 diabetes mellitus. No insulin is administered in this trial - insulin is dispensed into an empty vial.

Enrollment: 60 patients

Sex: All

Ages: 40 to 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Type 2 diabetes
• Insulin naive
• No previous experience administering injections

Exclusion criteria

• Any condition that, in the Investigator and/or Sponsor's opinion, could interfere with the results of this trial